Physician profile
Jaffer Khan
NPI 1366453540
$5,604.45
in general payments reported to CMS, 2019-2025
30 companies · $824 in 2025
The $824 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,224 · 2020: $547 · 2021: $783 · 2022: $624 · 2023: $445 · 2024: $1,157 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,103 · Travel and Lodging: $228 · Education: $95.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,103.08 |
| Travel and Lodging | $227.55 |
| Education | $95.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,401.04 | 2019-2024 | Xifaxan |
| Abbvie INC. | $744.89 | 2019-2025 | |
| Janssen Biotech, INC. | $541.23 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Medtronic, INC. | $374.19 | 2024-2025 | Interstim |
| Madrigal Pharmaceuticals | $343.61 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $300.32 | 2019-2025 | Livdelzi |
| Merck Sharp & Dohme LLC | $288.50 | 2019-2023 | Dificid |
| Amgen INC. | $201.02 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $188.18 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $151.34 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $136.66 | 2020-2024 | Ocaliva |
| Allergan, INC. | $133.20 | 2019 | |
| Braintree Laboratories, INC. | $102.17 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $99.86 | 2019-2021 | |
| Celgene Corporation | $91.16 | 2021-2023 | Zeposia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $70.37 | 2019-2023 | Gattex |
| Intra-Sana Laboratories | $70.27 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.79 | 2021 | |
| Redhill Biopharma INC. | $50.84 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Ferring Pharmaceuticals INC. | $45.97 | 2019 | |
| Nestle Healthcare Nutrition INC. | $40.62 | 2021-2022 | |
| Lilly USA, LLC | $35.34 | 2021-2022 | |
| Fujifilm Healthcare Americas Corporation | $34.03 | 2023 | Fujifilm |
| Acelrx Pharmaceuticals, INC. | $19.38 | 2021 | |
| Boston Scientific Corporation | $17.65 | 2025 | Axonics |
| E.R. Squibb & Sons, L.L.C. | $16.30 | 2022 | |
| Olympus America INC. | $15.27 | 2024 | Olympus |
| Astrazeneca Pharmaceuticals LP | $14.22 | 2021 | |
| Shire North American Group INC | $12.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaffer Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.